Table 4.
Objective Response by Treatment Regimen
| Tumor Response | Cis+Pac |
Cis+Vin |
Cis+Gem |
Cis+Top |
Total | ||||
|---|---|---|---|---|---|---|---|---|---|
| No. | % | No. | % | No. | % | No. | % | ||
| Responders | 30 | 29.1 | 28 | 25.9 | 25 | 22.3 | 26 | 23.4 | 109 |
| Complete | 3 | 2.9 | 8 | 7.4 | 1 | 0.9 | 2 | 1.8 | 14 |
| Partial | 27 | 26.2 | 20 | 18.5 | 24 | 21.4 | 24 | 21.6 | 95 |
| Stable disease | 50 | 48.4 | 46 | 42.6 | 54 | 48.2 | 53 | 47.8 | 203 |
| Progressive disease/other | 23 | 22.3 | 34 | 31.5 | 33 | 29.5 | 32 | 28.8 | 122 |
| Total | 103 | 108 | 112 | 111 | 434 | ||||
| Odds ratio* | — | 1.17 | 1.43 | 1.34 | |||||
| 95% CI† | — | 0.54 to 2.58 | 0.65 to 3.19 | 0.61 to 2.98 | |||||
Abbreviations: Cis+Pac, cisplatin + paclitaxel; Cis+Vin, cisplain + vinorelbine; Cis+Gem, cisplatin + gemcitabine; Cis+Top, cisplatin + topotecan.
*
Odds ratios for response are provided for the reference arm, Cis+Pac, to the experimental therapies.
†
CIs are adjusted with a Bonferroni correction.